phrykt

Adaptive Biotechnologies Corp (ADPT): who owns it and who trades it

As of Nov 16, 2026, ADPT insiders reported 184 open-market sales worth $127M and no purchases in the last 12 months, with 77% of the sale value made under pre-set 10b5-1 plans. The largest seller was Chad M Robins (CEO), with $34.1M. 8 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Adaptive Biotechnologies

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, ADPT insiders reported $0 of open-market purchases and $127M of sales. 77% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$127M
184 trades, 11 people
Sales under a 10b5-1 plan
77%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 13, 2026

Purchases and sales by month

$25.6M$25.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Julie RubinsteinPresidentSale plan11,466$28.93$332KForm 4
Nov 12, 2026Julie RubinsteinPresidentSale plan11,881$29.40$349KForm 4
Nov 11, 2026Julie RubinsteinPresidentSale plan4,983$30.29$151KForm 4
Nov 11, 2026Julie RubinsteinPresidentSale plan6,898$31.22$215KForm 4
Nov 11, 2026Susan BobulskyChief Commercial OfficerSale plan1,875$32.00$60KForm 4
Nov 10, 2026Julie RubinsteinPresidentSale plan9,981$29.35$293KForm 4
Nov 10, 2026Julie RubinsteinPresidentSale plan1,900$30.41$57.8KForm 4
Nov 9, 2026Julie RubinsteinPresidentSale plan1,100$28.87$31.8KForm 4
Nov 9, 2026Julie RubinsteinPresidentSale plan8,381$30.15$253KForm 4
Nov 9, 2026Julie RubinsteinPresidentSale plan2,400$30.58$73.4KForm 4
Nov 6, 2026Julie RubinsteinPresidentSale plan8,400$27.32$229KForm 4
Nov 6, 2026Julie RubinsteinPresidentSale plan3,481$27.88$97.1KForm 4
Nov 5, 2026Julie RubinsteinPresidentSale plan5,926$26.10$155KForm 4
Nov 5, 2026Julie RubinsteinPresidentSale plan5,455$26.88$147KForm 4
Nov 5, 2026Julie RubinsteinPresidentSale plan500$27.70$13.8KForm 4
Nov 4, 2026Julie RubinsteinPresidentSale plan4,000$25.78$103KForm 4
Nov 4, 2026Julie RubinsteinPresidentSale plan7,881$26.60$210KForm 4
Nov 3, 2026Julie RubinsteinPresidentSale plan11,881$25.98$309KForm 4
Nov 2, 2026Julie RubinsteinPresidentSale plan9,296$25.23$235KForm 4
Nov 2, 2026Julie RubinsteinPresidentSale plan2,585$26.34$68.1KForm 4
Oct 30, 2026Julie RubinsteinPresidentSale plan9,486$26.55$252KForm 4
Oct 30, 2026Julie RubinsteinPresidentSale plan2,395$27.45$65.7KForm 4
Oct 29, 2026Julie RubinsteinPresidentSale plan11,881$28.27$336KForm 4
Oct 28, 2026Julie RubinsteinPresidentSale plan11,681$28.44$332KForm 4
Oct 28, 2026Julie RubinsteinPresidentSale plan200$28.90$5.8KForm 4
Oct 27, 2026Julie RubinsteinPresidentSale plan3,000$26.58$79.7KForm 4
Oct 27, 2026Julie RubinsteinPresidentSale plan8,881$27.53$244KForm 4
Oct 26, 2026Julie RubinsteinPresidentSale plan8,503$25.94$221KForm 4
Oct 26, 2026Julie RubinsteinPresidentSale plan3,378$26.30$88.8KForm 4
Oct 23, 2026Julie RubinsteinPresidentSale plan4,500$24.50$110KForm 4
Oct 23, 2026Julie RubinsteinPresidentSale plan7,381$25.28$187KForm 4
Oct 22, 2026Julie RubinsteinPresidentSale plan10,181$24.38$248KForm 4
Oct 22, 2026Julie RubinsteinPresidentSale plan1,700$25.29$43KForm 4
Oct 21, 2026Julie RubinsteinPresidentSale plan5,999$25.25$151KForm 4
Oct 21, 2026Julie RubinsteinPresidentSale plan5,882$25.57$150KForm 4
Oct 20, 2026Julie RubinsteinPresidentSale plan11,781$24.53$289KForm 4
Oct 20, 2026Julie RubinsteinPresidentSale plan100$24.85$2.5KForm 4
Oct 19, 2026Julie RubinsteinPresidentSale plan11,881$24.05$286KForm 4
Oct 16, 2026Julie RubinsteinPresidentSale plan11,581$24.21$280KForm 4
Oct 16, 2026Julie RubinsteinPresidentSale plan300$25.45$7.6KForm 4
Oct 15, 2026Julie RubinsteinPresidentSale plan11,881$25.61$304KForm 4
Oct 14, 2026Julie RubinsteinPresidentSale plan6,781$25.57$173KForm 4
Oct 14, 2026Julie RubinsteinPresidentSale plan5,100$25.82$132KForm 4
Oct 13, 2026Julie RubinsteinPresidentSale plan11,881$25.50$303KForm 4
Oct 12, 2026Julie RubinsteinPresidentSale plan9,181$25.35$233KForm 4
Oct 12, 2026Julie RubinsteinPresidentSale plan2,700$26.07$70.4KForm 4
Oct 9, 2026Julie RubinsteinPresidentSale plan11,881$26.41$314KForm 4
Oct 8, 2026Julie RubinsteinPresidentSale plan11,881$25.66$305KForm 4
Oct 7, 2026Julie RubinsteinPresidentSale plan11,881$26.40$314KForm 4
Oct 6, 2026Julie RubinsteinPresidentSale plan9,381$27.36$257KForm 4
Oct 6, 2026Julie RubinsteinPresidentSale plan1,100$28.21$31KForm 4
Oct 6, 2026Julie RubinsteinPresidentSale plan901$29.71$26.8KForm 4
Oct 6, 2026Julie RubinsteinPresidentSale plan499$30.53$15.2KForm 4
Oct 6, 2026Susan BobulskyChief Commercial OfficerSale plan6,444$30.00$193KForm 4
Oct 5, 2026Julie RubinsteinPresidentSale plan6,699$28.82$193KForm 4
Oct 5, 2026Julie RubinsteinPresidentSale plan5,182$29.67$154KForm 4
Oct 2, 2026Julie RubinsteinPresidentSale plan11,881$28.13$334KForm 4
Oct 1, 2026Francis LoChief People OfficerSale plan8,094$27.52$223KForm 4
Oct 1, 2026Francis LoChief People OfficerSale plan18,698$28.61$535KForm 4
Oct 1, 2026Julie RubinsteinPresidentSale plan6,081$27.57$168KForm 4
Oct 1, 2026Julie RubinsteinPresidentSale plan5,800$28.56$166KForm 4
Sep 16, 2026Francis LoChief People OfficerSale plan107,537$28.02$3MForm 4
Sep 16, 2026Francis LoChief People OfficerSale plan7,869$28.57$225KForm 4
Sep 15, 2026Susan BobulskyChief Commercial OfficerSale plan1,195$27.00$32.3KForm 4
Aug 26, 2026Katey Einterz OwenDirectorSale9,615$26.00$250KForm 4
Aug 18, 2026Robert HershbergDirectorSale15,000$24.39$366KForm 4
Aug 18, 2026Robert HershbergDirectorSale15,664$24.41$382KForm 4
Aug 18, 2026Chad M RobinsCEOSale204$25.14$5.1KForm 4
Aug 18, 2026Chad M RobinsCEOSale278,472$24.48$6.8MForm 4
Aug 17, 2026Chad M RobinsCEOSale2,525$25.57$64.6KForm 4
Aug 17, 2026Chad M RobinsCEOSale318,799$25.08$8MForm 4
Aug 17, 2026Peter M NeupertDirectorSale69,690$25.16$1.8MForm 4
Aug 17, 2026Peter M NeupertDirectorSale40,000$25.10$1MForm 4
Aug 17, 2026Peter M NeupertDirectorSale15,000$25.23$378KForm 4
Aug 10, 2026Susan BobulskyChief Commercial OfficerSale plan3,000$25.00$75KForm 4
Jul 30, 2026Susan BobulskyChief Commercial OfficerSale plan1,299$24.00$31.2KForm 4
Jul 21, 2026Harlan S RobinsChief Scientific OfficerSale plan213,702$22.12$4.7MForm 4
Jul 21, 2026Harlan S RobinsChief Scientific OfficerSale plan278,698$21.72$6.1MForm 4
Jul 16, 2026Susan BobulskyChief Commercial OfficerSale plan5,000$23.00$115KForm 4
Jul 15, 2026Francis LoChief People OfficerSale plan105,762$22.59$2.4MForm 4
Jul 2, 2026Harlan S RobinsChief Scientific OfficerSale plan239,351$21.74$5.2MForm 4
Jul 2, 2026Harlan S RobinsChief Scientific OfficerSale plan146,889$22.45$3.3MForm 4
Jul 2, 2026Francis LoChief People OfficerSale plan44,838$22.59$1MForm 4
Jul 1, 2026Francis LoChief People OfficerSale plan8,743$22.18$194KForm 4
Jul 1, 2026Francis LoChief People OfficerSale plan42,261$22.50$951KForm 4
Jul 1, 2026Susan BobulskyChief Commercial OfficerSale plan487$22.00$10.7KForm 4
Jun 29, 2026Sharon BenzenoChief Commercial Ofc ImmSale plan154,768$21.14$3.3MForm 4
Jun 26, 2026Sharon BenzenoChief Commercial Ofc ImmSale plan11,034$21.00$232KForm 4
Jun 25, 2026Susan BobulskyChief Commercial OfficerSale plan5,000$20.50$102KForm 4
Jun 25, 2026Michelle Renee GriffinDirectorSale plan52,084$20.18$1.1MForm 4
Jun 16, 2026Harlan S RobinsChief Scientific OfficerSale plan6,160$18.01$111KForm 4
Jun 15, 2026Harlan S RobinsChief Scientific OfficerSale plan100,000$17.37$1.7MForm 4
Jun 11, 2026Susan BobulskyChief Commercial OfficerSale plan5,000$19.00$95KForm 4
Jun 4, 2026Francis LoChief People OfficerSale plan39,741$17.49$695KForm 4
Jun 4, 2026Susan BobulskyChief Commercial OfficerSale plan11,000$18.00$198KForm 4
May 18, 2026Kyle PiskelCFOSale3,115$13.04$40.6KForm 4
Apr 27, 2026Julie RubinsteinPresidentSale plan19,037$14.23$271KForm 4
Apr 24, 2026Julie RubinsteinPresidentSale plan19,060$14.02$267KForm 4
Apr 23, 2026Julie RubinsteinPresidentSale plan19,060$13.74$262KForm 4
Apr 22, 2026Julie RubinsteinPresidentSale plan19,060$14.13$269KForm 4

Latest 100 of 184 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Chad M RobinsCEO and Chairman, Director–$34.1MAug 18, 2026
Harlan S RobinsChief Scientific Officer–$29.5MJul 21, 2026
Julie RubinsteinPresident and COO–$23.6MNov 13, 2026
Sharon BenzenoChief Commercial Ofc Imm Med–$14.7MJun 29, 2026
Francis LoChief People Officer–$13.9MOct 1, 2026
Kyle PiskelChief Financial Officer–$3.6MMay 18, 2026
Peter M NeupertDirector–$3.1MAug 17, 2026
Michelle Renee GriffinDirector–$2MJun 25, 2026
Susan BobulskyChief Commercial Officer, MRD–$1.5MNov 11, 2026
Robert HershbergDirector–$1.1MAug 18, 2026
Katey Einterz OwenDirector–$250KAug 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ADPT short interest

Moderate short interest. 7.1% of ADPT shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 29%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.48M ADPT shares were sold short, 7.1% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 1.89M shares, buying them all back would take about 6.1 trading days (days to cover).

Shares short, % of all shares

7.09%May 15Oct 309.00%

Days to cover

6.1May 15Oct 308.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.48M7.09%-4%1.89M6.1
Oct 15, 202611.99M7.51%+1%2.38M5.0
Sep 30, 202611.84M7.42%-12%2.67M4.4
Sep 15, 202613.49M8.45%+15%1.71M7.9
Aug 31, 202611.71M7.34%-12%1.84M6.4
Aug 14, 202613.32M8.35%+7%2.33M5.7
Jul 31, 202612.49M7.83%+10%2.84M4.4
Jul 15, 202611.40M7.12%+0%2.65M4.3
Jun 30, 202611.35M7.09%+48%5.09M2.2
Jun 15, 20267.65M4.78%-7%2.71M2.8
May 29, 20268.24M5.15%-7%1.61M5.1
May 15, 20268.90M5.56%+5%1.96M4.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Adaptive Biotechnologies company events

Adaptive Biotechnologies filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Jul 29, 2026LeadershipThe Company’s Chief Scientific Officer and Co-founder, Dr. Harlan Robins, decided to transition into a strategic consultant role with the Company. Filing
  3. Jun 22, 2026AgreementAdaptive Biotechnologies Corporation issued $345 million in of 0% Convertible Senior Notes due 2031. Filing
  4. Jun 15, 2026AnnouncementAdaptive Biotechnologies Corporation issued a press release announcing that it intends to offer, subject to market conditions and other factors, $250 million in of convertible senior notes due 2031 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the… Filing
  5. Jun 9, 2026VoteReported shareholder vote results. Filing
  6. May 5, 2026ResultsReleased financial results. Filing
  7. Feb 5, 2026ResultsReleased financial results. Filing
  8. Jan 12, 2026ResultsReleased financial results. Filing
  9. Dec 30, 2025AnnouncementAdaptive Biotechnologies Corporation announced that Digital Biotechnologies, Inc., a 70% owned subsidiary of the Company, held an initial closing of its Series A Preferred Stock financing, with total anticipated proceeds in the financing round of up to $15 million. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Adaptive Biotechnologies financials

Famous investors that hold ADPT

8 of the 50 well-known investors we track reported holding ADPT in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $867M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 202629.99M$867M2.7%No change
Cathie Wood · ARK Investment ManagementQ3 20261.92M$55.5M0.3%-8%
Israel Englander · Millennium ManagementQ3 20261.22M$35.1M0.0%+141%
Jim Simons · Renaissance TechnologiesQ3 2026867,100$25.1M0.0%+186%
Steve Cohen · Point72 Asset ManagementQ3 2026630,283$18.2M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026233,354$6.7M0.0%+29%
Ray Dalio · Bridgewater AssociatesQ3 202671,735$2.1M0.0%+79%
Paul Tudor Jones · Tudor Investment CorpQ3 202653,601$1.5M0.0%-90%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Adaptive Biotechnologies Corp (ADPT) stock

Are ADPT insiders buying or selling?

In the last 12 months, ADPT insiders reported no open-market purchases and 184 sales worth $127M. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in ADPT?

As of Oct 30, 2026, 11.48M ADPT shares were sold short, 7.1% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 1.89M shares, buying them all back would take about 6.1 trading days (days to cover). See the history.

Which famous investors hold ADPT?

8 of the 50 well-known investors we track reported ADPT in their latest 13F filing, including Andreas Halvorsen, Cathie Wood, Israel Englander. The largest position is worth $867M. See all holders.

Executive pay

Adaptive Biotechnologies's chief executive was paid a total of $9.1M for the year ended Dec 31, 2025, up 83% from $5M the year before. In the last 12 months, Adaptive Biotechnologies's executives and directors bought no stock on the open market and sold $127M.

Chief executive, total pay$9.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$39.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.